---
title: "China SXT Pharmaceuticals, Inc. (SXTC.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/SXTC.US.md"
symbol: "SXTC.US"
name: "China SXT Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
---

# China SXT Pharmaceuticals, Inc. (SXTC.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [www.sxtchina.com](https://www.sxtchina.com) |

## Company Profile

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:12.000Z

**Overall: D (0.70)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 169 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -15.42% |  |
| Net Profit YoY | -253.06% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.12 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.50M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.54M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -50.30% | E |
| Profit Margin | -576.72% | E |
| Gross Margin | 16.23% | D |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -15.42% | E |
| Net Profit YoY | -253.06% | E |
| Total Assets YoY | -14.98% | E |
| Net Assets YoY | 34.58% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -17.34% | D |
| OCF YoY | -15.42% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.05 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 23.22% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - China SXT Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-50.30%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-576.72%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "16.23%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-15.42%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-253.06%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-14.98%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "34.58%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-17.34%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-15.42%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.05",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "23.22%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Eli Lilly (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | Roche (US.RHHBY) | A | B | B | D | C | B |
| 04 | AstraZeneca (US.AZN) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.28 | 76/256 | 33.44 | 5.14 | 3.84 |
| PB | 0.12 | 4/256 | 11.99 | 10.07 | 0.54 |
| PS (TTM) | 1.63 | 45/256 | 105.97 | 90.64 | 7.13 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/SXTC.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/SXTC.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/SXTC.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.